Timothy Eugene Sullivan Sells 2,892 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan sold 2,892 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $19.79, for a total transaction of $57,232.68. Following the transaction, the chief financial officer owned 104,188 shares of the company’s stock, valued at approximately $2,061,880.52. The trade was a 2.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Timothy Eugene Sullivan also recently made the following trade(s):

• On Tuesday, January 13th, Timothy Eugene Sullivan sold 3,856 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $22.19, for a total transaction of $85,564.64.

Apellis Pharmaceuticals Trading Up 2.3%

NASDAQ APLS traded up $0.48 during mid-day trading on Wednesday, reaching $20.95. 3,345,624 shares of the stock were exchanged, compared to its average volume of 3,186,931. The company has a debt-to-equity ratio of 0.90, a current ratio of 3.54 and a quick ratio of 3.10. The stock has a market cap of $2.65 billion, a P/E ratio of 67.58 and a beta of 0.31. The stock has a 50 day simple moving average of $22.93 and a 200-day simple moving average of $23.52. Apellis Pharmaceuticals, Inc. has a one year low of $16.10 and a one year high of $31.17.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Thursday, October 30th. The company reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.64. The firm had revenue of $458.58 million during the quarter, compared to analyst estimates of $364.58 million. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The business’s quarterly revenue was up 133.0% on a year-over-year basis. During the same period last year, the company posted ($0.46) EPS. On average, analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. PNC Financial Services Group Inc. raised its holdings in shares of Apellis Pharmaceuticals by 0.8% in the second quarter. PNC Financial Services Group Inc. now owns 58,856 shares of the company’s stock valued at $1,019,000 after purchasing an additional 465 shares during the last quarter. Wedmont Private Capital grew its position in Apellis Pharmaceuticals by 4.1% in the 4th quarter. Wedmont Private Capital now owns 11,883 shares of the company’s stock worth $315,000 after purchasing an additional 468 shares in the last quarter. Amalgamated Bank increased its stake in Apellis Pharmaceuticals by 6.9% in the 3rd quarter. Amalgamated Bank now owns 8,674 shares of the company’s stock valued at $196,000 after buying an additional 563 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Apellis Pharmaceuticals by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,855 shares of the company’s stock worth $84,000 after buying an additional 655 shares in the last quarter. Finally, Parallel Advisors LLC lifted its position in shares of Apellis Pharmaceuticals by 80.0% during the 2nd quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock worth $33,000 after buying an additional 855 shares in the last quarter. 96.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on APLS. Mizuho dropped their price target on Apellis Pharmaceuticals from $24.00 to $19.00 and set a “neutral” rating on the stock in a research note on Monday, November 3rd. HC Wainwright lowered their target price on Apellis Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating on the stock in a research report on Friday, October 31st. Stifel Nicolaus cut their target price on Apellis Pharmaceuticals from $55.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, December 19th. The Goldman Sachs Group restated a “sell” rating and set a $19.00 price target on shares of Apellis Pharmaceuticals in a research note on Monday, January 12th. Finally, Wall Street Zen raised shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Twelve analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Apellis Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $33.53.

More Apellis Pharmaceuticals News

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: Bank of America upgraded Apellis from neutral to buy and set a $28 price target, citing strong early launch trajectory for the company’s kidney-disease therapy — a clear near-term catalyst for revenue upside. Apellis upgraded at BofA on launch trajectory for kidney disease therapy
• Positive Sentiment: An analyst note in Benzinga highlights that current valuation may underappreciate Empaveli (the company’s therapy) potential and early uptake in a rare kidney-disease market, signaling a possible multi-year revenue inflection if adoption continues. Apellis Valuation Ignores Empaveli Potential, Says Analyst
• Neutral Sentiment: Wells Fargo trimmed its price target from $29 to $26 but kept an overweight rating, reflecting a modest reset to near-term expectations while still projecting upside versus current levels. Wells Fargo trims price target to $26
• Neutral Sentiment: RBC Capital reiterated a hold rating for Apellis, indicating some analysts remain cautious despite positive launch signals. RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
• Negative Sentiment: Two insiders sold shares on Jan. 20 — CFO Timothy Sullivan sold 2,892 shares and General Counsel David Watson sold 2,475 shares. While both still hold large positions, insider sales can be perceived negatively by investors monitoring insider conviction. Form 4 – Timothy Eugene Sullivan Form 4 – David O. Watson

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.